25.4 C
New York
Saturday, June 13, 2026

Tag: Johnson

Sealed Air Names Kristen Actis-Grande Chief Financial Officer

CHARLOTTE, N.C., Aug. 4, 2025 /PRNewswire/ -- Sealed Air Corporation (NYSE: SEE) today announced Kristen Actis-Grande will join the company as Chief Financial Officer,...

Transocean Ltd. Reports Second Quarter 2025 Results

STEINHAUSEN, Switzerland, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today reported a net loss attributable to controlling interest of $938 million, $1.06 per diluted share, for the three months ended June 30, 2025.

Silicon Labs Extends IoT Security Leadership with World’s First PSA Level 4 Certification

Series 3 Secure Vault, debuting on the SiXG301 SoC in the next-gen Series 3 lineup, achieves highest security certification for advanced IoT protection AUSTIN, Texas,...

Johnson Fistel, PLLP Investigates Telephone and Data Systems, Fluence Energy, The Bancorp, and Zynex on Behalf of Long-Term Shareholders

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of the following companies: Telephone and Data Systems, Inc. (NYSE: TDS), Fluence Energy, Inc. (NASDAQ: FLNC), The Bancorp, Inc. (NASDAQ: TBBK), and Zynex, Inc. (NASDAQ: ZYXI). Long-term shareholders who have held shares continuously since before certain cutoff dates may have standing to pursue corporate governance reform initiatives designed to protect the companies and investors from future harm resulting from alleged governance failures.

Johnson Fistel Continues Investigation on Behalf of Proficient Auto Logistics, Inc. (PAL) Shareholders

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Proficient Auto Logistics, Inc. (NASDAQ: PAL) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

Johnson Outdoors Reports Fiscal Third Quarter Results

RACINE, Wis., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Outdoors Inc. (Nasdaq:JOUT), a leading global innovator of outdoor recreation equipment and technology, today announced operating results for the Company’s third fiscal quarter ending June 27, 2025.

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

Woodforest National Bank Supports Flood Relief For Texas Hill Country

Woodforest among three presenting sponsors of the "Band Together Texas" benefit concert THE WOODLANDS, Texas, July 31, 2025 /PRNewswire/ -- Woodforest National Bank is honored to...

Contango Announces Production Results for the Quarter Ended June 30, 2025

FAIRBANKS, Alaska, July 30, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO) announces production results at the Peak Gold...

Air Canada Expands Landline Luxury Motorcoach Service, Connects Kingston to its Global Network

Multimodal service in partnership with The Landline Company links Kingston Norman Rogers Airport to Toronto Pearson International AirportPremium, Canadian built motorcoaches are fully accessible and...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsJohnson